Desk screen

Desk Screen Report

Scope Assessment

This manuscript presents original research on the molecular mechanisms of pathological vascular maturation in rheumatoid arthritis (RA), combining spatial transcriptomics, cell culture, organoid studies, and pharmacological validation. The work is clearly within scope for In Silico: it makes testable claims about cellular and molecular mechanisms, presents empirical evidence, and includes sufficient methodological detail for evaluation.

Threshold Issues

Completeness: The submission is complete. Methods are detailed, figures are present, data are described, and supplementary information is provided.

Clarity: The manuscript is clearly written and the central claim is intelligible: that fibroblast-derived neurotrophin signaling, regulated by NOTCH3, drives abnormal vascular maturation in RA synovia, and that FDA-approved TRK inhibitors can reverse this process.

Fundamental flaws: No obvious fatal flaw is apparent on its face. The experimental design is coherent (spatial transcriptomics → mechanistic studies → therapeutic validation), and the logic connecting evidence to conclusions is traceable.

Venue Fit

The work is appropriate for In Silico's audience. It addresses a specific disease mechanism using multi-modal evidence (transcriptomics, histology, cell biology, tissue explants). The claims are scaled to the evidence presented, and the authors acknowledge limitations (e.g., 6-month treatment window, need for longer-term studies). The work does not make clinical guidance claims that would trigger the clinical safety desk-rejection criterion.

Quality Indicators

• Evidence quality: Spatial transcriptomics on 22 RA patients with paired pre/post-treatment samples; validation across multiple orthogonal methods (RNAscope, immunohistochemistry, Western blot, qPCR)
• Reproducibility: Detailed protocols, cell lines and tissue sources specified, reagents identified
• Novelty: The NOTCH3-neurotrophin-mural cell axis in RA appears to be a previously unreported mechanism
• Limitations acknowledged: Authors note the 6-month timepoint limitation and the need for further studies on nerve coupling

Potential Concerns (for reviewers, not desk-rejection)

These are substantive but not threshold issues:

1. The causal chain from NOTCH3 → NGF → NGFR/TRK signaling → mural cell differentiation relies on correlative spatial data plus in vitro/ex vivo validation; in vivo confirmation would strengthen claims
2. TRK inhibitor efficacy is demonstrated only in synovial explants, not in vivo
3. The clinical relevance of persistent vascular maturation despite immunosuppression is asserted but not directly demonstrated (e.g., no correlation with clinical outcomes)

These are appropriate for peer review, not grounds for desk rejection.

---

DESK DECISION: proceed

This manuscript meets the threshold for full review. It presents original, well-documented research with a clear mechanistic hypothesis, multiple lines of supporting evidence, and potential therapeutic implications. The claims are appropriately scaled to the evidence, and the work is reproducible as written. Send to panel.